Company Description: Isosterix is developing a differentiated small-molecule inhibitor of Kat6A, an epigenetic oncogene which is amplified and implicated in multiple tumor types, including breast cancer. Kat6A is amplified in the 8p11-p12 breast cancer amplicon; this amplification has been found in about 15% of human breast cancer and is associated with poor prognosis. PF-07248144 (Pfizer) is in Phase 1/2 trials in ER+/HER2- breast cancer as single agent and in combination with SERDs and CDK4/6 inhibitors. In published studies, Kat6 inhibitors have been shown to be active in breast cancer xenograft CDx and PDx models and in hematological cancers in a MYC-driven lymphoma mouse model. With a unique biological mechanism, inducing senescence and cell cycle arrest without DNA damage, Kat6A inhibition represents a new epigenetic target which is not associated with genotoxicity. Isosterix inhibitors have demonstrated efficacy in ER+/HER2- Breast Cancer xenografts and are unique and differentiated with selectivity for Kat6A over paralog Kat6B, enhancing their therapeutic potential. Candidate Selection is ongoing with toxicology studies in progress. Isosterix will be presenting at AACR in April 2024 and is initiating licensing/partnering discussions.